Horizon Therapeutics | Patient Daily

Horizon Therapeutics

Patient Daily | May 7, 2023

Horizon Therapeutics plc Reports First-Quarter 2023 Financial Results

Patient Daily | May 7, 2023

Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab for the Treatment of Lupus Nephritis

Patient Daily | May 7, 2023

Horizon Therapeutics plc Ranks First in Patient Centricity and Integrity by Patient Advocacy Groups According to New PatientView Survey

Patient Daily | May 7, 2023

Horizon Therapeutics plc Announces Initiation of Phase 3 Clinical Trial in Japan Evaluating TEPEZZA® (teprotumumab-trbw) in Adults with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED)

Patient Daily | May 7, 2023

Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)

Patient Daily | Apr 24, 2023

Horizon Therapeutics plc Announces UPLIZNA® (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be Presented at the 2023 American Academy of Neurology (AAN) Annual Meeting

Patient Daily | Apr 24, 2023

Horizon Therapeutics plc and Massachusetts Institute of Technology (MIT) Solve Announce the Launch of the Third Annual Horizon Prize to Inspire Sustainable Solutions for Research and Care in the Rare Disease Community

Patient Daily | Apr 24, 2023

Horizon Therapeutics Announces Date of Irish Court Hearing to Sanction Scheme of Arrangement

Trending

Patient Daily | Sep 17, 2025

Patients Come First spokesperson: Drug ads 'are putting lives at risk by encouraging people to abandon essential treatments'

+ Pharmaceuticals

Patient Daily | Sep 23, 2025

Wall Street Journal editorial board alleges hospitals misuse 340B program

Patient Daily | Sep 17, 2025

PhRMA’s Senior Director on 340B: 'State and federal investigations have shown 340B is often exploited for profit'

+ Pharmaceuticals

Patient Daily | Sep 22, 2025

Nurses United for Healthcare Integrity says hospitals abuse 340B drug pricing program